Log In Get Started

Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

23,632 total articles

BullFrog AI Provides Business Update: Strengthened Balance Sheet Supports Continued Execution as Company Aims to Ramp Commercial Activity with Global Pharmaceutical and Biotechnology Partners
Apr 12, 2026
Avery Klein
Press Releases

BullFrog AI Provides Business Update: Strengthened Balance Sheet Supports Continued Execution as Company Aims to Ramp Commercial Activity with Global Pharmaceutical and Biotechnology Partners

BullFrog AI Holdings announced a significant commercial feasibility agreement with a top 5 global pharmaceutical company to use its AI platform bfLEAP® to identify novel drug targets in major depressive disorder. The company also strengthened its balance sheet with recent financings to support operations into late 2027 and is advancing multiple dis…

BFRG
ASP Isotopes Inc. Provides Business Update
Apr 12, 2026
Derek Hwang
Press Releases

ASP Isotopes Inc. Provides Business Update

ASP Isotopes Inc. presents a comprehensive business update highlighting operational milestones across its nuclear medicine, electronics, and nuclear energy platforms. The company anticipates first commercial shipments of several enriched isotopes including Silicon-28, Carbon-14, and Ytterbium-176 in 2026, expects to reach helium production capacity…

ASPI
Palvella Therapeutics Appoints John D. Doux, M.D., M.B.A., Dermatologist and Recognized Leader in Rare Skin Diseases, to Board of Directors
Apr 12, 2026
Leila Farooq
Press Releases

Palvella Therapeutics Appoints John D. Doux, M.D., M.B.A., Dermatologist and Recognized Leader in Rare Skin Diseases, to Board of Directors

Palvella Therapeutics, a clinical-stage biopharmaceutical company specializing in rare skin diseases and vascular malformations, announced the appointment of John D. Doux, M.D., M.B.A., a recognized dermatologist and investor in rare skin disease therapies, to its Board of Directors. Dr. Doux's deep medical experience and previous advocacy for inno…

PVLA
NorthStrive Biosciences Announces U.S. Arrival of EL-32 Working Cell Bank and Initiation of Manufacturing Optimization for Dual Myostatin Assets Targeting Muscle Preservation with GLP-1 Therapies in Collaboration with Modulant Biosciences
Apr 12, 2026
Priya Menon
Press Releases

NorthStrive Biosciences Announces U.S. Arrival of EL-32 Working Cell Bank and Initiation of Manufacturing Optimization for Dual Myostatin Assets Targeting Muscle Preservation with GLP-1 Therapies in Collaboration with Modulant Biosciences

PMGC Holdings Inc.'s subsidiary NorthStrive Biosciences announces the successful transfer of the EL-32 Working Cell Bank to a U.S.-based fermentation facility, initiating manufacturing optimization aimed at scalable and cost-effective production. EL-32 is an engineered probiotic therapeutic targeting muscle preservation by modulating myostatin and …

ELAB
3D Systems Accelerates Production-Scale Additive Manufacturing with New High-Throughput Platform and Next-Generation Factory Software
Apr 12, 2026
Sofia Navarro
Press Releases

3D Systems Accelerates Production-Scale Additive Manufacturing with New High-Throughput Platform and Next-Generation Factory Software

3D Systems has unveiled its next-generation SLA 825 Dual stereolithography system offering 22% larger build volume and up to 25% faster print speeds to enhance production throughput. Alongside, it launched AddiTrak™, an advanced on-premises factory software platform for real-time fleet monitoring and process control. These innovations aim to accele…

DDD
Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer
Apr 12, 2026
Derek Hwang
Press Releases

Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer

Revolution Medicines announced positive topline results from the RASolute 302 Phase 3 clinical trial evaluating daraxonrasib, an oral targeted therapy, in previously treated metastatic pancreatic ductal adenocarcinoma patients. The trial met all primary and key secondary endpoints, showing a significant improvement in progression-free survival and …

RVMD
CVRx Reports Preliminary First Quarter 2026 Financial Results
Apr 12, 2026
Derek Hwang
Press Releases

CVRx Reports Preliminary First Quarter 2026 Financial Results

CVRx, Inc. announced preliminary unaudited financial results for Q1 2026, reporting approximately 20% revenue growth year over year to $14.7-$14.8 million. The company noted improvements in Medicare Advantage prior authorization approval rates following implementation of Category I CPT codes, and activated the first site in the BENEFIT-HF clinical …

CVRX
Eupraxia Pharmaceuticals to Present at Upcoming Investor Conferences
Apr 12, 2026
Caleb Monroe
Press Releases

Eupraxia Pharmaceuticals to Present at Upcoming Investor Conferences

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company specializing in local, controlled drug delivery using its Diffusphere™ technology, announced participation in upcoming investor conferences in New York and Toronto. The company is advancing clinical trials for its lead products, including EP-104GI for eosinophilic esophagitis and…

EPRX
Elite Express Holding Inc. Reports First Quarter 2026 Results
Apr 12, 2026
Ajmal Hussain
Press Releases

Elite Express Holding Inc. Reports First Quarter 2026 Results

Elite Express Holding Inc. reported first quarter 2026 financial results showing a 16.3% year-over-year revenue increase to $805,298 and a 46.3% reduction in net loss to $110,104. Improvements were driven by increased delivery volumes, better route and fleet management, and labor efficiency. The renewal of its ISP agreement with FedEx contributed t…

ETS
VisionWave Acquires xClibre™ AI Video Intelligence IP Assets
Apr 12, 2026
Jordan Park
Press Releases

VisionWave Acquires xClibre™ AI Video Intelligence IP Assets

VisionWave Holdings, a Nasdaq-listed defense technology company, has acquired the xClibre AI video intelligence intellectual property valued at approximately $60 million. The acquisition enhances VisionWave's sensing architecture by adding AI-driven video analytics to their existing RF-based detection systems. The company plans to integrate xClibre…

VWAV
Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism
Apr 12, 2026
Hana Yamamoto
Press Releases

Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism

Septerna, Inc., a clinical-stage biotech company focused on GPCR drug discovery, has initiated a Phase 1 clinical trial for SEP-479, an oral small molecule PTH1R agonist designed to treat hypoparathyroidism. The trial will assess safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers, with data expected by late 2026 or e…

SEPN
Bitcoin Depot Appoints New Compliance Officer, Tony Gagliardi
Apr 12, 2026
Avery Klein
Press Releases

Bitcoin Depot Appoints New Compliance Officer, Tony Gagliardi

Bitcoin Depot announced the hiring of Tony Gagliardi as Chief Compliance Officer to lead and enhance the company's compliance framework amid evolving regulatory requirements. Gagliardi brings over 15 years of experience across financial services and digital assets, overseeing anti-money laundering, Know-Your-Customer programs, and state-level regul…

BTM
OSS to Support Network of Autonomous Energy Nodes for Emerging Alternative Energy-Powered Data Center Company
Apr 12, 2026
Caleb Monroe
Press Releases

OSS to Support Network of Autonomous Energy Nodes for Emerging Alternative Energy-Powered Data Center Company

One Stop Systems, Inc. (NASDAQ: OSS) announced a purchase order exceeding $500,000 from a renewable-energy tech firm developing a network of autonomous energy nodes powering onboard AI compute payloads. This marks the start of a projected multi-year relationship with follow-on orders exceeding $1 million annually, potentially scaling to $10 million…

OSS